公开(公告)号：US09771643B2

公开(公告)日：2017-09-26

申请号：US14245229

申请日：2014-04-04

申请人： Akihito Ninomiya ,  Yoshinari Okada ,  Takahiro Miyazaki ,  Yasushi Matsumura ,  Shinichiro Kato ,  Tetsuya Shimomura

发明人： Akihito Ninomiya ,  Yoshinari Okada ,  Takahiro Miyazaki ,  Yasushi Matsumura ,  Shinichiro Kato ,  Tetsuya Shimomura ,  Katsuya Yamaguchi

IPC分类号： C23C8/22 ,  C23C8/02 ,  C23C8/80

CPC分类号： C23C8/22 ,  C23C8/02 ,  C23C8/80

摘要： The invention provides a carburized part which has excellent medium-cycle fatigue strength in particular subjected to surface-hardening treatment by carburization. The invention provides a carburized part including a carburized layer formed by performing carburizing treatment to a steel, the steel including, in terms of % by mass: 0.15% to 0.25% of C, 0.15% or less of Si, 0.4% to 1.1% of Mn, 0.8% to 1.4% of Cr, 0.25% to 0.55% of Mo, 0.015% or less of P, and 0.035% or less of S, with the remainder being Fe and unavoidable impurities, and the steel satisfying the following relation; 0.10≦[Mo]/(10[Si]+[Mn]+[Cr])≦0.40, in which [M] represents a content of element M in terms of % by mass.

公开(公告)号：US08911566B2

公开(公告)日：2014-12-16

申请号：US12958855

申请日：2010-12-02

申请人： Isamu Saito ,  Yoshihiro Takitani ,  Shinichiro Kato ,  Makoto Hobo ,  Keiichiro Kamiya ,  Takahiro Miyazaki ,  Takashi Kano

发明人： Isamu Saito ,  Yoshihiro Takitani ,  Shinichiro Kato ,  Makoto Hobo ,  Keiichiro Kamiya ,  Takahiro Miyazaki ,  Takashi Kano

IPC分类号： F16C3/06 ,  B21K1/08

CPC分类号： F16C3/06 ,  B21K1/08 ,  C23C8/32 ,  Y10T29/49286 ,  Y10T74/2173

摘要： A nitrocarburized crankshaft member made of a steel that includes C in an amount by weight of 0.25 to 0.32% as a required element and an optional element that may be included, and Fe and inevitable impurities in a remaining portion. The steel-made crankshaft member mainly includes ferrite and perlite, wherein at least a portion of the steel surface thereof having a ferrite surface area of 50% or greater is imparted with a nitrocarburized hard layer. The nitrocarburized hard layer includes a surface compound layer suppressed to a thickness of 10 to 35 μm, and a nitrogen diffusion zone below the surface compound layer having a diffusion depth of 700 μm or greater. The steel includes C, Si, Mn, Cu, Ni, and Cr as the required elements and Mo, N, s-Al, and Ti as the optional elements.

摘要翻译： 由钢制成的氮碳共渗曲轴构件，其包含作为所需元素的重量为0.25〜0.32％的C和可以包含的任选元素，剩余部分中的Fe和不可避免的杂质。 钢制曲轴构件主要包括铁素体和珍珠岩，其中具有铁素体表面积为50％以上的钢表面的至少一部分被赋予了氮碳共渗硬化层。 氮碳共渗硬化层包括被抑制为10〜35μm厚度的表面化合物层和扩散深度为700μm以上的表面化合物层下方的氮扩散区。 钢包含C，Si，Mn，Cu，Ni和Cr作为所需元素，Mo，N，s-Al和Ti作为任选元素。

公开(公告)号：US20120076798A1

公开(公告)日：2012-03-29

申请号：US13240356

申请日：2011-09-22

申请人： Steven W. Granger ,  Shinichiro Kato ,  Carl F. Ware

发明人： Steven W. Granger ,  Shinichiro Kato ,  Carl F. Ware

IPC分类号： A61K39/395 ,  C12N15/13 ,  C12N1/21 ,  C12P21/00 ,  C12N5/16 ,  C07K16/24 ,  C12N5/10

CPC分类号： C07K16/24 ,  A61K2039/505 ,  C07K16/2875 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76

摘要： Provided herein are antibodies that immunospecifically bind to an hLIGHT polypeptide; isolated nucleic acids encoding the antibodies; vectors and host cells comprising nucleic acids encoding the antibodies; methods of making the antibodies; and a method of treating a hLIGHT-mediated disease in a subject comprising administering to the subject the antibodies. In preferred embodiments, the anti-hLIGHT antibodies provided herein will ameliorate, neutralize or otherwise inhibit hLIGHT biological activity in vivo (e.g., the hLIGHT-mediated production or secretion of CCL20, IL-8 or RANTES from a cell expressing a hLIGHT receptor). Also provided herein is a method for the detection of hLIGHT in a sample as well as a method for ameliorating, neutralizing or otherwise inhibiting hLIGHT activity, e.g., in a human subject suffering from a disorder in which hLIGHT activity is detrimental.

摘要翻译： 本文提供了免疫特异性结合于hLIGHT多肽的抗体; 编码抗体的分离的核酸; 载体和宿主细胞，其包含编码抗体的核酸; 制备抗体的方法; 以及治疗受试者中的hLIGHT介导的疾病的方法，包括向受试者施用抗体。 在优选的实施方案中，本文提供的抗hLIGHT抗体将改善，中和或抑制体内的hLIGHT生物活性（例如，hLIGHT介导的来自表达hLIGHT受体的细胞的CCL20，IL-8或RANTES的产生或分泌）。 本文还提供了用于检测样品中的hLIGHT的方法以及用于改善，中和或抑制hLIGHT活性的方法，例如在患有hLIGHT活性有害的病症的人类受试者中。

公开(公告)号：US08124091B2

公开(公告)日：2012-02-28

申请号：US11577695

申请日：2005-12-05

申请人： Shinichiro Kato ,  Rongfang Wang

发明人： Shinichiro Kato ,  Rongfang Wang

IPC分类号： A61K39/42

CPC分类号： C07K16/1018 ,  A01K2217/05 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/71 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92

摘要： Human, humanized and chimeric monoclonal antibodies that bind to influenza M2 protein. A human monoclonal antibody that binds to influenza M2 protein having different amino acid sequences. The antibodies are useful for, among other things, treatment, diagnostics, purifying and isolating M2 or influenza virus, and identifying the presence of M2 or influenza virus in a sample or a subject.

摘要翻译： 结合流感M2蛋白的人，人源化和嵌合单克隆抗体。 与具有不同氨基酸序列的流感M2蛋白结合的人单克隆抗体。 抗体可用于治疗，诊断，纯化和分离M2或流感病毒，以及鉴定样品或受试者中M2或流感病毒的存在。

公开(公告)号：US08003106B2

公开(公告)日：2011-08-23

申请号：US12039632

申请日：2008-02-28

申请人： Toshifumi Mikayama ,  Rongfang Wang ,  Shinichiro Kato

发明人： Toshifumi Mikayama ,  Rongfang Wang ,  Shinichiro Kato

IPC分类号： A61K39/42 ,  A61K39/145

CPC分类号： C07K16/1018 ,  A01K2217/075 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/76

摘要： Human, humanized and chimeric monoclonal antibodies that bind to influenza M2 protein. The antibodies are useful for, among other things, treatment, diagnostics, purifying and isolating M2 or influenza virus, and identifying the presence of M2 or influenza virus in a sample or a subject.

摘要翻译： 结合流感M2蛋白的人，人源化和嵌合单克隆抗体。 抗体可用于治疗，诊断，纯化和分离M2或流感病毒，以及鉴定样品或受试者中M2或流感病毒的存在。

公开(公告)号：US20080204281A1

公开(公告)日：2008-08-28

申请号：US12071215

申请日：2008-02-19

申请人： Masahiro Sugiura ,  Hiromichi Naitoh ,  Munenori Matsumoto ,  Noriaki Okada ,  Shinichiro Kato ,  Tomoji Mabuchi ,  Haruyuki Ikeo ,  Masataka Okado ,  Kouichi Mizuno ,  Tomotsugu Sekine

发明人： Masahiro Sugiura ,  Hiromichi Naitoh ,  Munenori Matsumoto ,  Noriaki Okada ,  Shinichiro Kato ,  Tomoji Mabuchi ,  Haruyuki Ikeo ,  Masataka Okado ,  Kouichi Mizuno ,  Tomotsugu Sekine

IPC分类号： G08G1/123

CPC分类号： G08G1/005 ,  B60R25/24 ,  B60R25/33 ,  G07C9/00111 ,  G07C9/00309 ,  G07C2009/00793 ,  G08G1/0969 ,  G08G1/205

摘要： An electronic key system includes an in-vehicle unit mounted in a vehicle and a portable unit. When a user leaves the vehicle, the in-vehicle unit requests information on a relative position of the vehicle relative to a landmark object near the vehicle from a vehicle navigation device and transmits received relative position information to the portable unit. The portable unit stores the received relative position information, and notifies of the stored relative position information according to a user's operation.

摘要翻译： 电子钥匙系统包括安装在车辆中的车载单元和便携式单元。 当用户离开车辆时，车内单元从车辆导航装置请求关于车辆相对于车辆附近的地标物体的相对位置的信息，并将接收到的相对位置信息发送到便携式单元。 便携式装置存储接收到的相对位置信息，并根据用户的操作来通知存储的相对位置信息。

公开(公告)号：US4833156A

公开(公告)日：1989-05-23

申请号：US160600

申请日：1988-02-26

申请人： Masayuki Sakakibara ,  Yuzi Munezuka ,  Shinichiro Kato

发明人： Masayuki Sakakibara ,  Yuzi Munezuka ,  Shinichiro Kato

IPC分类号： A61K31/40 ,  A61K31/401 ,  A61K31/635 ,  A61P25/28 ,  C07D207/48

CPC分类号： A61K31/635 ,  A61K31/40

摘要： A use of the pyrrolidone derivative represented by the following formula [I] as an anti-amnesitc agent: ##STR1## wherein R represents a group ##STR2## X represents --SO.sub.2 -- or --CO--; R' represents a hydrogen atom, a lower alkyl group, a trifluoromethyl group, a halogen atom or a nitro group; n denotes an integer of 1-5; and, when n is an integer of 2 or more, R' may be the same or different, provided that(a) when X is --SO.sub.2 --, there is no case where R' is 3-CF.sub.3, 4-Cl-5-CF.sub.3, 3,5-(CF.sub.3).sub.2 or 3-NO.sub.2 ;(b) when X is --CO--, there is no case where n denotes 1 or 2 and R' is a halogen atom or a nitro group;(c) when X is --SO.sub.2 --, there is no case where n denotes 1 or 2 and R' is a group other than 4-Cl or 3-NO.sub.2 ; and(d) when n denotes 2, there is no case where the groups R' represent the same group which is halogen atom or a nitro group.Typical pyrrolidone derivatives are N-(4'-toluene-sulfonyl)-2-pyrrolidone, N-(4'-chlorobenzenesulfonyl)-2-pyrrolidone, N-benzenesulfonyl-2-pyrrolidone and N-[4'-(1", 1"-dimethylethyl)benzoyl]-2-pyrrolidone, particularly N-(4'-chloro-benzenesulfonyl)-2-pyrrolidone.

公开(公告)号：US08685177B2

公开(公告)日：2014-04-01

申请号：US12630536

申请日：2009-12-03

申请人： Isamu Saito ,  Yoshihiro Takitani ,  Shinichiro Kato ,  Makoto Hobo ,  Keiichiro Kamiya ,  Takahiro Miyazaki ,  Takashi Kano

发明人： Isamu Saito ,  Yoshihiro Takitani ,  Shinichiro Kato ,  Makoto Hobo ,  Keiichiro Kamiya ,  Takahiro Miyazaki ,  Takashi Kano

IPC分类号： C21D8/00 ,  C21D9/30 ,  C23C8/26

CPC分类号： F16C3/06 ,  B21K1/08 ,  C23C8/32 ,  Y10T29/49286 ,  Y10T74/2173

摘要： The invention relates to a crankshaft member having high fatigue strength and good bending correctability, and its method of manufacture. The steel made crankshaft member mainly consists of a two-phase structure of ferrite and perlite. The steel includes C, Ni, Mn, and Cr as required elements and Si, Cu, Mo, Ti, V, Nb, Ca, and S as optional elements that may be included, in the amounts of C within the range of 0.20 to 0.50 wt %, Si within the range of 0 to 0.6 wt %, Mn within the range of 0.5 to 1.5 wt %, Cu within the range of 0 to 0.7 wt %, Ni within the range of 0.05 to 1.5 wt %, Cr within the range of 0.05 to 0.45 wt %, and Mo within the range of 0 to 0.5 wt % to satisfy the condition 115≧70C+8Si+23Mn+11Cu+128Cr+83Mo≧50. A portion of the member surface is provided at least with a hard nitride layer having an average hardness within the range of 300 to 450 HV. Lamellar spacing of the perlite is 0.3 μm or less.

摘要翻译： 本发明涉及具有高疲劳强度和良好的弯曲矫正性的曲轴件及其制造方法。 钢制曲轴构件主要由铁素体和珍珠岩的两相结构组成。 所述钢包含C，Ni，Mn和Cr作为要素，Si，Cu，Mo，Ti，V，Nb，Ca和S作为可以包含的任意元素，C的量在0.20〜 0.50重量％，Si在0〜0.6重量％的范围内，Mn在0.5〜1.5重量％的范围内，Cu在0〜0.7重量％的范围内，Ni在0.05〜1.5重量％的范围内，Cr在 0.05〜0.45重量％的范围，Mo在0〜0.5重量％的范围内，满足条件115≥70℃+ 8Si + 23Mn + 11Cu + 128Cr +83Mo≥50。 构件表面的一部分至少设置有平均硬度在300至450HV范围内的硬质氮化物层。 珍珠岩的层状间隔为0.3μm以下。

公开(公告)号：US08461307B2

公开(公告)日：2013-06-11

申请号：US13240356

申请日：2011-09-22

申请人： Steven W. Granger ,  Shinichiro Kato ,  Carl F. Ware

发明人： Steven W. Granger ,  Shinichiro Kato ,  Carl F. Ware

IPC分类号： C12P21/08

CPC分类号： C07K16/24 ,  A61K2039/505 ,  C07K16/2875 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76

摘要： Provided herein are antibodies that immunospecifically bind to an hLIGHT polypeptide; isolated nucleic acids encoding the antibodies; vectors and host cells comprising nucleic acids encoding the antibodies; methods of making the antibodies; and a method of treating a hLIGHT-mediated disease in a subject comprising administering to the subject the antibodies. In preferred embodiments, the anti-hLIGHT antibodies provided herein will ameliorate, neutralize or otherwise inhibit hLIGHT biological activity in vivo (e.g., the hLIGHT-mediated production or secretion of CCL20, IL-8 or RANTES from a cell expressing a hLIGHT receptor). Also provided herein is a method for the detection of hLIGHT in a sample as well as a method for ameliorating, neutralizing or otherwise inhibiting hLIGHT activity, e.g., in a human subject suffering from a disorder in which hLIGHT activity is detrimental.

摘要翻译： 本文提供了免疫特异性结合于hLIGHT多肽的抗体; 编码抗体的分离的核酸; 载体和宿主细胞，其包含编码抗体的核酸; 制备抗体的方法; 以及治疗受试者中的hLIGHT介导的疾病的方法，包括向受试者施用抗体。 在优选的实施方案中，本文提供的抗hLIGHT抗体可改善，中和或抑制体内的hLIGHT生物活性（例如，hLIGHT介导的来自表达hLIGHT受体的细胞的CCL20，IL-8或RANTES的产生或分泌）。 本文还提供了用于检测样品中的hLIGHT的方法以及用于改善，中和或抑制hLIGHT活性的方法，例如在患有hLIGHT活性有害的病症的人类受试者中。

公开(公告)号：US08283450B2

公开(公告)日：2012-10-09

申请号：US12087436

申请日：2006-11-27

申请人： Shinichiro Kato ,  Rachel Soloff Nugent ,  Hitoshi Yoshida ,  Michael Croft

发明人： Shinichiro Kato ,  Rachel Soloff Nugent ,  Hitoshi Yoshida ,  Michael Croft

IPC分类号： C12P21/08

CPC分类号： C07K16/2878 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/30 ,  C07K2317/565 ,  C07K2317/71 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  C12N2799/026

摘要： The invention provides antibodies that specifically bind to OX40 (CD134), referred to as OX40 antibodies, anti-OX40 or anti-OX40 antibodies. Invention antibodies that specifically bind to OX40 include mammalian (human, primate, etc.), humanized and chimeric anti-OX40 antibodies. Invention antibodies and antibody subsequences (fragments) that specifically bind to OX40 include purified and isolated antibodies, as well as pharmaceutical formulations thereof, are useful in various methods including treatment, screening and detection methods.

摘要翻译： 本发明提供特异性结合OX40（CD134），称为OX40抗体，抗OX40或抗OX40抗体的抗体。 特异性结合OX40的本发明抗体包括哺乳动物（人，灵长类动物等），人源化和嵌合抗OX40抗体。 特异性结合OX40的本发明抗体和抗体子序列（片段）包括纯化和分离的抗体及其药物制剂，可用于各种方法，包括治疗，筛选和检测方法。